

**PORTON**



Enabling the Public's Early Access to  
Good Medicines

# NEWSLETTER

May 2025





# Contents

---

01 | Technical Enabling

---

02 | Services & Solutions

---

03 | Company Events

---

04 | ESG

---

05 | Marketing Activities

---

# Technical Enabling

## Flow Chemistry: A New Technology to Enhance the Traditional Batch Process in the Delivery Requirement

2025-06-04

In the pharmaceutical manufacturing of active pharmaceutical ingredients (APIs), scale-up production often faces significant challenges. Some reactions carry substantial safety risks, while others suffer from drastically reduced efficiency compared to laboratory-scale reactions or are even difficult to achieve. By transforming chemical reactions into inherently small-scale, continuously fed and discharged micro-reactions through flow chemistry technology, these scale-up challenges can be largely overcome.



**Flow Chemistry:**  
A New Technology to Enhance the Traditional Batch Process in the Delivery Requirement

A CUSTOMER-CENTRIC, INNOVATIVE AND RELIABLE CDMO WITH GLOBAL SOLUTIONS

CASESTUDY PORTON

### Introduction

In the pharmaceutical manufacturing of active pharmaceutical ingredients (APIs), scale-up production often faces significant challenges. Some reactions carry substantial safety risks, while others suffer from drastically reduced efficiency compared to laboratory-scale reactions or are even difficult to achieve. By transforming chemical reactions into inherently small-scale, continuously fed and discharged micro-reactions through flow chemistry technology, these scale-up challenges can be largely overcome.

The characteristics of flow chemistry technology primarily include:

1. Enhanced Mixing Capability: Improved mass transfer eliminates concentration gradients.
2. High Surface-to-Volume Ratio: Structural features enable rapid heat transfer (fast cooling/heating) and precise temperature control.
3. Accurate Residence Time: Residence time is strictly determined by reactor characteristics (channel length, volume) and flow rate.

Compared to batch reactors, continuous reactors are hundreds to thousands of times smaller in volume. Leveraging their excellent heat and mass transfer properties, reaction parameters are far easier to control, enabling conditions that would be nearly impossible in batch reactors.

Continuous reaction can effectively solve the problem of "amplification effect" in batch processes from research and development to pilot testing, and then again to commercial production. Porton's continuous reaction capabilities include low-temperature nitration reaction, ozone oxidation reaction, nitrification reaction, high-temperature reaction, and organic acid reaction, etc., which can achieve process development and technology transfer from research and development to production application. This article will explain the actual cases of the results separately.

A CUSTOMER-CENTRIC, INNOVATIVE AND RELIABLE CDMO WITH GLOBAL SOLUTIONS

Free to Download

# Services & Solutions

## Porton Pharma Solutions Ltd. Conquers Complex POC Project Through Collaborative Innovation

2025-05-26

Recently, Porton Pharma Solutions Ltd. earned high praise from a client for its outstanding performance on a complex proof-of-concept (POC) project involving oligonucleotide and peptide, underscoring its prowess in tackling intricate projects. Entrusted by a Chinese innovative drug company, Porton faced multiple hurdles, including challenging process development, stringent impurity control, and rigorous quality standards. Porton swiftly assembled a cross-disciplinary team of experts in oligonucleotide R&D, peptide R&D, purification, analysis, and a dedicated project management to tackle these challenges collaboratively.



[Read more](#)

# Company Events

## Porton Pharma Solutions Celebrates 20 Years of Excellence and Innovation

2025-05-26

Chongqing, China – As the wheel of time turned to mark two extraordinary decades, Porton Pharma Solutions, one of the global leaders in Contract Development and Manufacturing Organization (CDMO) services, recently celebrated its 20th anniversary with a grand celebration in Chongqing, China. Global partners and industry leaders gathered to honor this pivotal milestone, celebrating Porton’s journey from its humble beginnings to a trusted enabler of global healthcare innovation.




[Read more](#)

## Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

2025-05-22

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics. Porton Advanced will provide end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress.



[Read more](#)

## Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC Transplantation Therapy

2025-05-22

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on cell therapy drugs for ophthalmic diseases. Porton Advanced will provide comprehensive CDMO services to support iPSC-derived retinal pigment epithelium cell (RPEC) therapy program, including CMC development and IND application assistance, to accelerate the therapy development progress.



[Read more](#)

# Customer Recognition

At Porton, we remain committed to being customer-centric, innovative, and providing reliable global solutions to accelerate patients' access to life-changing medicines.

**Subject:** [redacted] support

Hello

It was about two months ago when we initiated the conversation requesting J-Star NMR analytical support for synthesis. Many thanks for your collaboration with the team. We are pleased and prepared and we look forward to future collaboration.

Dear [redacted],

Thank you for the update. I am pleased to see how well the process went for both products, but particularly [redacted] given the gap in production experience for you and your team. Please accept my sincere gratitude for all the excellent work that went into these campaigns and share it with everyone who was involved in the process. Without their actions, it would not have been possible.

Have a nice holiday

Best regards,

Regards,

Dear Porton Team,

I think you heard today the resounding thanks and kudos for a job well done on this investigation.

Very impressive work, well done to you All!!

Dear [redacted],

Thanks [redacted] as the work has come to an end, I would sincerely like to thank Suya and the rest of the Porton team for an excellent job done. This was my first experience with Porton, and I must say it was a very pleasant one.

Sincerely

"Everyone who participated in the visit was highly impressed by Porton's professionalism, dedication, and technical capabilities."

A...Inc.

"..... As the work has come to an end, I would sincerely like to thank Suya and the rest of the Porton team for an excellent job done. This was my first experience with Porton, and I must say it was a very pleasant one"

A...Pharmaceuticals

"Many thanks to your expertise in process and data interpretation in close collaboration with the Porton China team, the root causes and the identification of the unknown impurity were successfully concluded."

A...Inc.

Please accept my sincere gratitude for all the excellent work that went into these campaigns and share it with everyone who was involved in the process. Without their actions, it would not have been possible.

A...Inc.


# ESG

## Porton Announces 2030 Sustainability Targets on World Environment Day

2025-06-05

June 5, 2025, Chongqing — On the 54th World Environment Day, Porton Pharma Solutions Ltd. (Porton) officially announced its 2030 sustainability targets, highlighting its actions in response to the global sustainable development initiative and determination to transition into a greener future.

The sustainability targets cover three major areas: energy consumption, water resources and waste management. Together with the carbon reduction target validated by the SBTi in March, they constitute Porton's comprehensive sustainability objectives.



[Read more](#)

# Marketing Activities

## Previous Events

Swiss Biotech Day

May 5-6

Basel, Switzerland

BIO Korea 2025

May 7-9

Seoul, Korea

Boston ABI Lab Lunch and Learn

May 15

Natick MA, United States

CPhI Americas 2025

May 20-22

Pennsylvania Convention Center, Philadelphia, United States



2nd ADC Linker & Conjugation Summit

May 6-8

Boston MA, United States

ASGCT Annual Meeting

May 13-17

Portland, United States

CGCT 2025

May 16-17

Shenzhen, China



## Upcoming Events

[Stay Updated on the Latest Developments. Click to Schedule Your Appointment](#)

Events	Date	Venue	Booth
BOS Basel 2025	June 11-12	Basel, Switzerland	62
Exploring Therapeutic Frontiers Lunch & Learn	June 12	AC Hotel San Francisco, United States	/
EWOC: Empowering Women in Organic Chemistry	June 12-13	Chicago, Illinois, United States	/
BIO International Convention 2025	June 16-19	Boston MA, United States	1372
From Research and Development to Commercialization: A Seminar on Development and Regulatory Strategies for Cell and Gene Therapy Products	June 19	Beijing, China	/
The 7th David Grant Symposium	June 18-20	Minneapolis, Minnesota, United States	/
The 28th ACS Annual Green Chemistry & Engineering Conference	June 23-26	Pittsburgh, PA, United States	/
CPHI & PMEC China	June 24-26	Shanghai, China	E2A32
Interphex Week Tokyo 2025	July 9-11	Tokyo, Japan	E13–29
2025 Organic Reactions and Processes Gordon Research Conference	July 20-25	Bryant University, Smithfield, RI, United States	/
BIO Asia-Taiwan 2025	July 23-27	Taiwan, China	/

# Customized Development and Manufacturing Technical Solutions for Conventional and New Drug Modalities

OEB 1 to 5

Sub-g to Metric-ton Scale

Pre-clinical to Commercial



Small  
Molecules



Tides



Biologics and  
Conjugates



Advanced Therapy  
Medicinal Products

Operational Excellence

IP

QA

EHS

RA

PM

Supply Chain

Global Site Compliance



**PORTON**



# A Customer Centric, Innovative, and Reliable CDMO with Global Solutions

Please contact us to help you on your next development project and achieve your business goals.



**LinkedIn**

Porton Pharma Solutions

[business@portonpharma.com](mailto:business@portonpharma.com)  
[www.portonpharma.com](http://www.portonpharma.com)



Contact Us